|
|||||
|
|
| VIP方案治疗晚期非小细胞肺癌 | |
| 引用本文： | 赵文英 王潞. VIP方案治疗晚期非小细胞肺癌[J]. 皖南医学院学报, 2000, 19(2): 100-101 |
| 作者姓名： | 赵文英 王潞 |
| 作者单位： | 附属弋矶山医院肿瘤内科!241001 |
| 摘 要： | 采用VIP联合化疗方案治疗晚期复治的非小细胞肺癌24例。结果：CR1例，PR9例，NC9例，PD5例。有效率41．67％（10／24）。毒性反应主要是骨髓抑制及消化道反应。加用Mesna后，全组未出现肉眼血尿。提示VIP方案治疗晚期复治的非小细胞肺癌有较好疗效，值得推广使用。 |
| 关 键 词： | 癌 非小细胞肺 VIP方案 异环磷酰胺 顺铂 鬼臼乙叉甙 |
VIP Regimen in the Treatment of Advanced Non-Small Cell Lung Cancer |
|
| Zhao Wenying, Wang Lu, Ji Zhaoning. VIP Regimen in the Treatment of Advanced Non-Small Cell Lung Cancer[J]. Acta Academiae Medicinae Wannan, 2000, 19(2): 100-101 | |
| Authors: | Zhao Wenying Wang Lu Ji Zhaoning |
| Abstract: | Twenty-four patients with advanced and recurrent non-small cell lung cancer (NSCLC)were treated with combined-chemotherapy of etoposide (100mg, d1-5 ), Ifosfamide(2g, d1-5 ) and cisplatin (30mg, d1-5 ) (VIP regimen). A mong them one patient showed complete response, 9 showed partial response and no change response, and 5 showed progtessive disease, with an overall response rate of 41. 67% (10/24). The major toxic effects were myelosuppres sion and gastrointestinal tract reaction. No macroscopic hematuria was observed because of Mesna administered. This result suggests that VIP is an effective regimen for patients with advanced non-small cell lung cancer. |
| Keywords: | carcinoma non-small cell lung VIP regimen Ifosfamide Cisplatin Etoposide |
| 本文献已被 CNKI 维普 等数据库收录！ | |